Business Description
ProKidney Corp
NAICS : 541714
SIC : 8731
ISIN : US74291D1046
Share Class Description:
PROK: Ordinary Shares - Class ATotal Employee Number:
231Compare
Compare
Traded in other countries / regions
PROK.USAPROK.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2022-07-12Description
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 51.54 | |||||
Equity-to-Asset | -3.55 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.7 | |||||
3-Year EPS without NRI Growth Rate | -31.2 | |||||
3-Year FCF Growth Rate | 7.7 | |||||
3-Year Book Growth Rate | 26.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 230.01 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.97 | |||||
9-Day RSI | 72.72 | |||||
14-Day RSI | 66.27 | |||||
3-1 Month Momentum % | -9.83 | |||||
6-1 Month Momentum % | -29.41 | |||||
12-1 Month Momentum % | -33.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.36 | |||||
Quick Ratio | 8.36 | |||||
Cash Ratio | 7.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.1 | |||||
Shareholder Yield % | 0.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -21664.55 | |||||
Net Margin % | -10288.39 | |||||
EBITDA Margin % | -19549.14 | |||||
FCF Margin % | -19527.38 | |||||
OCF Margin % | -17257.58 | |||||
ROA % | -26.28 | |||||
ROIC % | -276.41 | |||||
3-Year ROIIC % | -25.49 | |||||
ROC (Joel Greenblatt) % | -306.64 | |||||
ROCE % | -56.94 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 287.15 | |||||
EV-to-EBIT | -8.09 | |||||
EV-to-Forward-EBIT | -1.02 | |||||
EV-to-EBITDA | -8.43 | |||||
EV-to-Forward-EBITDA | -1.02 | |||||
EV-to-Revenue | 1648.25 | |||||
EV-to-Forward-Revenue | 444.11 | |||||
EV-to-FCF | -8.44 | |||||
Earnings Yield (Greenblatt) % | -12.36 | |||||
FCF Yield % | -38.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PROK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProKidney Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.818 | ||
| EPS (TTM) ($) | -0.55 | ||
| Beta | 3.403 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.58 | ||
| Volatility % | 61.69 | ||
| 14-Day RSI | 66.27 | ||
| 14-Day ATR ($) | 0.108288 | ||
| 20-Day SMA ($) | 1.637 | ||
| 12-1 Month Momentum % | -33.9 | ||
| 52-Week Range ($) | 1.3 - 3.4799 | ||
| Shares Outstanding (Mil) | 208.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProKidney Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProKidney Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 67 days | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 1.64 (-1.20%) | ||
| General meeting for 2026 | 2026-05-28 10:00 | 1.81 (+5.85%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.71 (-2.84%) | ||
| Annual report for 2025 | 2026-03-18 | 2.13 (-2.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 2.13 (-2.29%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-14 08:15 | 2.29 (-2.55%) | ||
| Jefferies Global Healthcare Conference | 2025-11-17 | 2.41 (+8.56%) | ||
| Guggenheim Healthcare Innovation Conference | 2025-11-12 10:00 | 2.80 (+0.72%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 2.89 (+5.09%) |
Show
Entries
ProKidney Corp Frequently Asked Questions
What is ProKidney Corp(PROK)'s stock price today?
The current price of PROK is $2.01. The 52 week high of PROK is $3.48 and 52 week low is $1.30.
When is next earnings date of ProKidney Corp(PROK)?
The next earnings date of ProKidney Corp(PROK) is 2026-11-10 Est..
Does ProKidney Corp(PROK) pay dividends? If so, how much?
ProKidney Corp(PROK) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm | 2025-01-31 |
Articles on ProKidney Corp
ProKidney (PROK) Q2 Results Highlight Market's High Growth Expectations Despite Ongoing Losses
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers